Hypersialylation of β1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility

被引:279
作者
Seales, EC
Jurado, GA
Brunson, BA
Wakefield, JK
Frost, AR
Beilis, SL
机构
[1] Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA
[3] Tranzyme Inc, Res Triangle Pk, NC USA
关键词
D O I
10.1158/0008-5472.CAN-04-3117
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Colon adenocareinomas are known to express elevated levels of alpha 2-6 sialylation and increased activity of ST6Gal-I, the Golgi glycosyltransferase that creates alpha 2-6 linkages. Elevated ST6Gal-I positively correlates with metastasis and poor survival, and therefore ST6Gal-I-mediated hypersialylation likely plays a role in colorectal tumor invasion. Previously we found that oncogenic ras (present in roughly 50% of colon adenocarcinomas) up-regulates ST6Gal-I and, in turn, increases sialylation of beta(1) integrin adhesion receptors in colon epithelial cells. However, we wanted to know if this pattern held true in vivo and, if so, how beta(1) hypersialylation might contribute to colon tumor progression. In the present study, we find that 0] integrins from colon adenocarcinomas consistently carry higher levels of alpha 2-6 sialic acid. To explore the effects of increased alpha 2-6 sialylation on beta(1)-integrin function, we stably expressed ST6Gal-I in a colon epithelial cell line lacking endogenous ST6Gal-I. ST6GaI-I expressors (with alpha 2-6 sialylated beta(1) integrins) exhibited up-regulated attachment to collagen I and laminin and increased haptotactic migration toward collagen I relative to parental cells (with completely unsialylated beta(1) integrins). Blockade of ST6Gal-I expression with short interfering RNA reversed collagen binding back to the level of ST6Gal-I nonexpressors, confirming that alpha 2-6 sialylation regulates beta(1) integrin function. Finally, we show that beta(1) integrins from ST6Gal-I expressors have increased association with talin, a marker for integrin activation. Collectively, these findings suggest that beta(1) hypersialylation may augment colon tumor progression by altering cell preference for certain extracellular matrix milieus, as well as by stimulating cell migration.
引用
收藏
页码:4645 / 4652
页数:8
相关论文
共 56 条
[1]   The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death [J].
Amano, M ;
Galvan, M ;
He, JL ;
Baum, LG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (09) :7469-7475
[2]   Variant glycosylation:: an underappreciated regulatory mechanism for β1 integrins [J].
Bellis, SL .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2004, 1663 (1-2) :52-60
[3]  
Berditchevski F, 2001, J CELL SCI, V114, P4143
[4]   PREVALENCE OF RAS GENE-MUTATIONS IN HUMAN COLORECTAL CANCERS [J].
BOS, JL ;
FEARON, ER ;
HAMILTON, SR ;
VERLAANDEVRIES, M ;
VANBOOM, JH ;
VANDEREB, AJ ;
VOGELSTEIN, B .
NATURE, 1987, 327 (6120) :293-297
[5]   Expression of sialyi-Tn epitopes on β1 integrin alters epithelial cell phenotype, proliferation and haptotaxis [J].
Clément, M ;
Rocher, J ;
Loirand, G ;
Le Pendu, J .
JOURNAL OF CELL SCIENCE, 2004, 117 (21) :5059-5069
[6]   HUMAN COLON-CANCER CELL-LINES PERMANENTLY EXPRESSING ALPHA-2,6-SIALYLATED SUGAR CHAINS BY TRANSFECTION WITH RAT BETA-GALACTOSIDE ALPHA-2,6 SIALYLTRANSFERASE CDNA [J].
DALLOLIO, F ;
CHIRICOLO, M ;
LOLLINI, P ;
LAU, JTY .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 211 (02) :554-561
[7]  
DALLOLIO F, 2001, GLYCOCONJ J, V17, P669
[8]   Ras oncogene induces β-galactoside α2,6-sialyltransferase (ST6Gal I) via a RalGEF-mediated signal to its housekeeping promoter [J].
Dalziel, M ;
Dall'Olio, F ;
Mungul, A ;
Piller, V ;
Piller, F .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2004, 271 (18) :3623-3634
[9]   Integrin signaling: it's where the action is [J].
Damsky, CH ;
Ilic, D .
CURRENT OPINION IN CELL BIOLOGY, 2002, 14 (05) :594-602
[10]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954